| Not Yet Recruiting | Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) NCT06226662 | NovelMed Therapeutics | Phase 2 |
| Recruiting | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm NCT07246096 | Changhai Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases NCT07212322 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Ass NCT07160608 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07236762 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases NCT07236801 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases NCT07123519 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07104721 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis NCT04871191 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110 | Essen Biotech | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) NCT06294236 | Sana Biotechnology | Phase 1 |
| Recruiting | An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646 | China Immunotech (Beijing) Biotechnology Co., Ltd. | N/A |
| Recruiting | Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases NCT06316076 | RenJi Hospital | Phase 1 |
| Recruiting | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease NCT06056921 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Active Not Recruiting | An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases NCT05732402 | Alpine Immune Sciences, Inc. | Phase 1 / Phase 2 |
| Unknown | Stratified Therapy on Pediatric AAGN NCT05969522 | Wang Mo | Phase 4 |
| Active Not Recruiting | Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease NCT03323476 | Centre Hospitalier Departemental Vendee | Phase 3 |
| Completed | A Study of CCX168 in Japanese and Caucasian Healthy Adult Males NCT05988008 | Amgen | Phase 1 |
| Terminated | Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing NCT02749292 | Massachusetts General Hospital | Phase 4 |
| Completed | A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medic NCT06004947 | Amgen | Phase 1 |
| Completed | A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 NCT05988021 | Amgen | Phase 1 |
| Completed | A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX16 NCT06004960 | Amgen | Phase 1 |
| Unknown | Low-dose Glucocorticoid Vasculitis Induction Study NCT02198248 | Chiba University | Phase 4 |
| Unknown | Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculi NCT02180126 | Hillel Yaffe Medical Center | — |
| Terminated | The Clinical Efficacy of DFPP in Patients With AAGN NCT02294344 | Zhi-Hong Liu, M.D. | N/A |
| Completed | Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease. NCT04413149 | Peking Union Medical College Hospital | — |
| Completed | Rituximab Vasculitis Maintenance Study NCT01697267 | Cambridge University Hospitals NHS Foundation Trust | Phase 3 |
| Withdrawn | Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens NCT01275274 | University of North Carolina, Chapel Hill | Phase 2 |
| Withdrawn | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab NCT01275287 | University of North Carolina, Chapel Hill | Phase 2 |